Denison Mines Corp Ordinary Shares (Canada) vs Merck & Co., Inc. — how do they compare? Denison Mines Corp Ordinary Shares (Canada) trades at $2.38 (market cap $2.33B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 151.2× Denison Mines Corp Ordinary Shares (Canada)'s market cap, and Merck & Co., Inc. pays a 2.38% dividend while Denison Mines Corp Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Denison Mines Corp Ordinary Shares (Canada) for 0 Days and Merck & Co., Inc. for 98 Days on average.
| DNN | MRK | |
|---|---|---|
Market Cap | $2.33B | $352.29B |
Volume | 20,155,849 | 6,348,796 |
Sector | Energy | Health |
52-Week High | $4.37 | $156.43 |
52-Week Low | $2.27 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $2.17B | $399.05B |
Dividend Yield | — | 2.38% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Denison Mines is a uranium mining, development, and exploration company focused on Canada's Athabasca Basin. Its portfolio includes the Wheeler River project and interests in other uranium projects and processing facilities.
Read more on DNN →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →